SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla spurts on receiving Establishment Inspection Report from USFDA for Indore facility

13 Oct 2016 Evaluate

Cipla is currently trading at Rs. 590.15, up by 9.60 points or 1.65% from its previous closing of Rs 580.55 on the BSE.

The scrip opened at Rs. 593.50 and has touched a high and low of Rs. 598.90 and Rs. 588.00 respectively. So far 133878 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 704.75 on 29-Oct-2015 and a 52 week low of Rs. 458.25 on 25-May-2016.

Last one week high and low of the scrip stood at Rs. 600.70 and Rs. 566.10 respectively. The current market cap of the company is Rs. 47436.35 crore.

The promoters holding in the company stood at 37.47%, while Institutions and Non-Institutions held 34.54% and 27.99% respectively.

Cipla has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Indore facility indicating formal closure of the USFDA inspection conducted in July/August, 2015.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.

Cipla Share Price

1232.95 -5.35 (-0.43%)
20-Apr-2026 14:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.15
Dr. Reddys Lab 1234.30
Cipla 1232.95
Zydus Lifesciences 938.40
Lupin 2329.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×